# Lung Cancer {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} *** ### **Overview** Lung cancer is one of the most lethal cancers globally, and NSCLC accounts for approximately 85% of cases. Curcumin has generated mechanistically rich and consistent preclinical evidence in NSCLC, with particular strength in three clinically significant areas: **reversal of cisplatin resistance**, **STAT3-driven chemoprevention**, and **radiosensitisation**. While large Phase III trial data are not yet available, the evidence base is substantially deeper than for many other natural compounds — including confirmed in vivo rodent model data, a liposomal curcumin cell study, and a registered clinical trial. *** ### Cisplatin Resistance Reversal: The ER Stress Mechanism Cisplatin resistance is one of the defining clinical challenges in advanced NSCLC. A significant proportion of patients who initially respond to platinum-based chemotherapy develop acquired resistance, and there are limited clinical options for restoring sensitivity. This is where curcumin's lung cancer evidence becomes most clinically meaningful. **Wang et al. (2022) — Curcumin increases cisplatin sensitivity in resistant NSCLC cells via ER stress:** This study used cisplatin-resistant NSCLC cell lines and investigated whether curcumin could restore sensitivity. The key findings: 1. Curcumin combined with cisplatin (DDP) significantly increased expression of ER stress markers — **CHOP, GRP78, XBP-1, ATF6, and caspase-4** — compared to either agent alone. The combination produced synergistic ER stress induction that neither drug achieved on its own. 2. Curcumin + cisplatin increased cleaved caspase-3 and cleaved PARP (confirmed by Western blotting) — markers of apoptosis execution — in resistant NSCLC cells that had previously survived cisplatin alone. 3. When the ER stress pathway was pharmacologically inhibited (using salubrinal), the chemosensitising effect of curcumin was suppressed — **confirming that ER stress pathway activation is the mechanistic requirement** for curcumin's cisplatin-sensitising effect, not a bystander observation. 4. Conclusion: *"Curcumin can increase the sensitivity of NSCLC to cisplatin through an ER stress pathway and can serve as one of the molecular targets for overcoming cisplatin resistance."* This is a specific, mechanistically confirmed finding — not a general "synergistic anti-cancer effect." It identifies a defined pathway (ER stress → CHOP/GRP78/ATF6 → caspase-4 activation → apoptosis) that curcumin activates in cisplatin-resistant cells, and it provides a rational basis for considering curcumin as an adjunct to platinum-based lung cancer regimens. **Cai et al. (2019) — Curcumin + cisplatin radiosensitisation in NSCLC A549 cells:** A separate study confirmed that curcumin, when combined with cisplatin and radiation, produced synergistic inhibition of proliferation, migration, and invasion in A549 NSCLC cells. The mechanism identified was inhibition of **EGFR-associated signalling pathways** — curcumin and cisplatin together suppressed EGFR protein expression and downstream cascade activity more effectively than either alone. EGFR inhibition reduced cancer cells' capacity for post-radiation repair and re-invasion, a finding directly relevant to concurrent chemoradiation protocols. *** ### STAT3 Inhibition and Chemoprevention STAT3 is aberrantly activated in approximately 50% of lung cancers and is a primary driver of tumour cell survival, proliferation, angiogenesis, and immune evasion in NSCLC. Curcumin is a well-characterised STAT3 inhibitor across multiple cancer types, and the lung cancer data on this pathway are among the most thoroughly evidenced. **Alexandrow et al. (2012) — Curcumin C3 Complex as a STAT3 pathway inhibitor for lung chemoprevention:** This study — which specifically used **Curcumin C3 Complex**, the same standardised formulation referenced throughout this library — found: 1. Dose-dependent suppression of **STAT3 phosphorylation at tyrosine-705** (Stat3-P) in both normal human bronchial epithelial cells and lung adenocarcinoma-derived H441 cells *in vitro* — confirming STAT3 inhibition in both preventive and therapeutic cell contexts 2. Dose-dependent reduction in cell proliferation in both cell types alongside STAT3-P suppression 3. **In vivo rodent model confirmation:** Curcumin-fed mice showed significantly reduced STAT3-P expression in lung tissue, alongside reduced expression of proliferative markers **Cyclin D1** and **Mcm2** — confirming that the in vitro STAT3 mechanism translates to living tissue 4. The authors concluded this work should inform a Phase II chemoprevention trial in former smokers — a clinically significant proposed application **Why this matters for group members:** STAT3 activation drives not only tumour cell survival in NSCLC, but also suppression of anti-tumour immune responses in the tumour microenvironment. Curcumin's STAT3 inhibition in lung tissue is therefore simultaneously anti-proliferative and potentially immune-modulatory — two mechanisms operating through the same target. **Curcumin and Resveratrol as Dual STAT3 Modulators (2025):** A 2025 review confirmed that curcumin's STAT3 suppression in lung cancer extends to inhibition of downstream targets, including **Cyclin D1,** and reduces the capacity of the STAT3/NF-κB axis to drive treatment resistance in NSCLC — providing updated mechanistic context and reinforcing the combination rationale for curcumin with polydatin/resveratrol, which also suppresses STAT3 via its own mechanisms. *** ### Liposomal Curcumin in Lung Cancer **Kokkinis et al. (2024) — Liposomal encapsulated curcumin in A549 lung adenocarcinoma cells:** This study used **PlexoZome®** liposomal curcumin formulation on A549 human lung adenocarcinoma cells and found: 1. Functional suppression of **proliferation, migration, and colony formation** — three independent measures of cancer cell aggressiveness 2. Suppression of cancer cell invasion capacity 3. Effects confirmed at concentrations achievable with liposomal oral delivery, unlike standard curcumin, which fails to reach therapeutic plasma concentrations at practical doses This is directly relevant to formulation choices. The study provides a clear biological rationale for why liposomal formulation matters specifically in lung cancer — the cellular concentrations required for STAT3 suppression, EGFR pathway inhibition, and ER stress induction in NSCLC cells are substantially more achievable with liposomal delivery than standard curcumin powder. *** ### Ferroptosis in NSCLC **Tang et al. — Curcumin induces ferroptosis in NSCLC cells via autophagy activation:** Curcumin can trigger ferroptosis — iron-dependent lipid peroxide-driven cell death — in NSCLC cells through an autophagy-linked mechanism. The specific pathway: 1. Curcumin activates autophagy in NSCLC cells 2. Autophagy-mediated degradation of **ferritin** (the iron storage protein) releases free intracellular iron 3. Elevated free iron drives Fenton-type reactions, generating lipid peroxides 4. Accumulation of lipid peroxides overwhelms GPX4-mediated defence, triggering ferroptosis This represents a **third independent cell death pathway** by which curcumin can kill NSCLC cells — alongside apoptosis (via caspase activation and Bax/Bcl-2 modulation) and ER stress-mediated death (via CHOP/GRP78/caspase-4). The ability to activate multiple distinct death pathways is clinically significant because chemotherapy-resistant NSCLC cells often survive by blocking one or two death pathways — curcumin's multi-pathway death induction means resistance to one mechanism does not confer resistance to curcumin overall. *** ### Curcumin + Piperlongumine Hybrid in NSCLC A curcumin-piperlongumine hybrid compound tested in H1299 NSCLC cells demonstrated: * Inhibition of cell growth * G2/M phase cell cycle arrest * Apoptosis induction via **JNK signalling regulation** This is noted because piperlongumine (from long pepper, closely related to piperine) is already used as a bioavailability enhancer for curcumin — the finding that a curcumin-piperlongumine hybrid retains and extends anti-cancer activity in NSCLC models adds mechanistic depth to the combination rationale beyond simple absorption enhancement. *** ### Registered Clinical Trial **ClinicalTrials.gov NCT01514266 — Effect of Curcumin on Lung Inflammation** A registered clinical study examining curcumin's effects on lung inflammation (NCT01514266) has been completed. This does not constitute a full Phase III cancer treatment trial, but it confirms that curcumin is progressing through the clinical research pipeline in lung cancer contexts and has been deemed safe enough for formal human investigation. *** ### Summary of Key Findings | Finding | Mechanism | Evidence Level | | --------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------- | | Cisplatin resistance reversal | ER stress pathway (CHOP/GRP78/ATF6/caspase-4) | Preclinical — confirmed in resistant NSCLC cell lines \[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC9232348/)]​ | | Radiosensitisation with cisplatin | EGFR pathway suppression | Preclinical — A549 cell line + radiation model \[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC6539728/)]​ | | STAT3 inhibition and chemoprevention | Stat3-P (Tyr-705) suppression; Cyclin D1/Mcm2 reduction | Preclinical in vitro + in vivo rodent model \[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC3319490/)]​ | | Ferroptosis induction | Autophagy-mediated ferritin degradation → lipid peroxidation | Preclinical — NSCLC cell line \[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605766/)]​ | | Liposomal curcumin anti-tumour activity | Proliferation, migration, colony formation suppression | Preclinical — A549 liposomal study \[[sciencedirect](https://www.sciencedirect.com/science/article/pii/S2405844024144404)]​ | | NF-κB/STAT3 dual suppression | Reduces treatment resistance and immune evasion | Multiple preclinical studies \[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12376182/)]​ | *** **Practical Interpretation** The evidence on curcumin for lung cancer is mechanistically richer and more consistent than many people may realise. Three independent death pathways (apoptosis, ER stress-driven death, and ferroptosis), two confirmed in vivo findings (rodent model STAT3 suppression; reversal of cisplatin resistance), and a liposomal-specific study collectively make this one of the better-supported cancer types in curcumin's evidence base — even without large Phase III trial data. The most clinically actionable findings are the reversal of cisplatin resistance via the ER stress mechanism and the suppression of the STAT3/EGFR pathway, both relevant to radiosensitisation. Both have direct potential application in discussions with integrative oncology teams for NSCLC patients on platinum-based or radiation-concurrent protocols. *** **References for Lung Cancer** * Curcumin increases sensitivity of NSCLC to cisplatin through ER stress pathway — Wang et al., 2022 — * Radiosensitisation effects of curcumin and cisplatin on NSCLC A549 cells — Cai et al., 2019 — * Curcumin: A Novel STAT3 Pathway Inhibitor for Lung Chemoprevention (C3 Complex in vitro + in vivo) — Alexandrow et al., 2012 — * Liposomal curcumin (PlexoZome®) attenuates lung cancer cell proliferation, migration and colony formation — Kokkinis et al., 2024 — * Curcumin induces ferroptosis in NSCLC cells via activating autophagy — Tang et al. — * Curcumin and Resveratrol as Dual STAT3 Modulators in Lung Cancer — Zamanian et al., 2025 — * Curcumin and its analogs in NSCLC — Tang et al., 2022 — * Investigating curcumin in NSCLC — Systematic review Guo et al., 2025 — --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/lung-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.